×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ESPR – esperion therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ESPR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/20
08:22 am
espr
Esperion (ESPR) Highlights Inclusion of Bempedoic Acid in 2026 ACC/AHA Dyslipidemia Guidelines [Yahoo! Finance]
Low
Report
Esperion (ESPR) Highlights Inclusion of Bempedoic Acid in 2026 ACC/AHA Dyslipidemia Guidelines [Yahoo! Finance]
3/17
08:29 am
espr
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session [Yahoo! Finance]
Low
Report
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session [Yahoo! Finance]
3/17
08:00 am
espr
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session
Neutral
Report
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session
3/16
06:30 am
espr
Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
Medium
Report
Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
3/15
08:16 pm
espr
Esperion Therapeutics Touts 38% Revenue Growth, Corstasis Deal and 2026 Cash-Gen Path at Conference [Yahoo! Finance]
Medium
Report
Esperion Therapeutics Touts 38% Revenue Growth, Corstasis Deal and 2026 Cash-Gen Path at Conference [Yahoo! Finance]
3/10
08:03 pm
espr
Esperion Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Esperion Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
3/10
03:12 pm
espr
Esperion Therapeutics Inc (ESPR) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
Low
Report
Esperion Therapeutics Inc (ESPR) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
3/10
03:02 pm
espr
Esperion Therapeutics (ESPR) had its "buy" rating reaffirmed by HC Wainwright.
Low
Report
Esperion Therapeutics (ESPR) had its "buy" rating reaffirmed by HC Wainwright.
Date
Time
Symbol
Company Name
Action
%Chg
3/10/2026
06:00 am
espr
esperion therapeutics, inc.
MISS
Report
-14.3%
esperion therapeutics, inc.
11/6/2025
06:00 am
espr
esperion therapeutics, inc.
MISS
Report
-4.2%
esperion therapeutics, inc.
8/5/2025
06:00 am
espr
esperion therapeutics, inc.
BEAT
Report
-0.6%
esperion therapeutics, inc.
5/6/2025
06:00 am
espr
esperion therapeutics, inc.
MISS
Report
-5.3%
esperion therapeutics, inc.
Date
Time
Symbol
Headline
Impact
3/18
04:14 pm
espr
Form 4 Esperion Therapeutics, For: Mar 17 Filed by: Looker Benjamin
Low
Report
Form 4 Esperion Therapeutics, For: Mar 17 Filed by: Looker Benjamin
3/18
04:13 pm
espr
Form 4 Esperion Therapeutics, For: Mar 17 Filed by: Koenig Sheldon L.
Low
Report
Form 4 Esperion Therapeutics, For: Mar 17 Filed by: Koenig Sheldon L.
3/18
04:13 pm
espr
Form 4 Esperion Therapeutics, For: Mar 17 Filed by: Halladay Benjamin
Low
Report
Form 4 Esperion Therapeutics, For: Mar 17 Filed by: Halladay Benjamin
3/17
03:20 pm
espr
Form 144 Esperion Therapeutics, Filed by: Halladay Benjamin
Low
Report
Form 144 Esperion Therapeutics, Filed by: Halladay Benjamin
3/17
03:18 pm
espr
Form 144 Esperion Therapeutics, Filed by: Looker Benjamin
Low
Report
Form 144 Esperion Therapeutics, Filed by: Looker Benjamin
3/17
03:13 pm
espr
Form 144 Esperion Therapeutics, Filed by: Koenig Sheldon L.
Low
Report
Form 144 Esperion Therapeutics, Filed by: Koenig Sheldon L.
3/16
04:21 pm
espr
Form 4 Esperion Therapeutics, For: Mar 13 Filed by: Looker Benjamin
Low
Report
Form 4 Esperion Therapeutics, For: Mar 13 Filed by: Looker Benjamin
3/16
04:20 pm
espr
Form 4 Esperion Therapeutics, For: Mar 13 Filed by: Koenig Sheldon L.
Low
Report
Form 4 Esperion Therapeutics, For: Mar 13 Filed by: Koenig Sheldon L.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/18
Form 8-K Esperion Therapeutics, For: Mar 14
18.2%
3/17 Esperion Therapeutics Inc (NASDAQ: ESPR) was upgraded by analysts at Citigroup Inc from a "neutral" rating to a "buy" rating. 14.6%
5/5 Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review 11.6%
11/17 Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions 10.0%
4/20 Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan 7.2%
1/31 Form 8-K Esperion Therapeutics, For: Jan 31 6.6%
2/12 Form SC 13G/A Esperion Therapeutics, Filed by: VANGUARD GROUP INC 5.9%
2/28 Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 5.2%
4/16 Form DEF 14A Esperion Therapeutics, For: May 28 4.6%
3/23 Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL™ (bempedoic acid) Tablet and Phase 2 Study Results of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet to be Presented at the American College of Cardiol 4.5%
3/17 Esperion Therapeutics Inc (NASDAQ: ESPR) was upgraded by analysts at Citigroup Inc from a "neutral" rating to a "buy" rating. 14.6%
5/5 Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review 11.6%
11/17 Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions 10.0%
4/20 Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan 7.2%
1/31 Form 8-K Esperion Therapeutics, For: Jan 31 6.6%
2/12 Form SC 13G/A Esperion Therapeutics, Filed by: VANGUARD GROUP INC 5.9%
2/28 Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 5.2%
4/16 Form DEF 14A Esperion Therapeutics, For: May 28 4.6%
3/23 Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL™ (bempedoic acid) Tablet and Phase 2 Study Results of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet to be Presented at the American College of Cardiol 4.5%
TOP News Decliners
2/27
Esperion Provides Lipid Management Franchise Updates; Reports Fourth Quarter and Full Year 2019 Financial Results
-11.2%
3/12 Form 4 Esperion Therapeutics, For: Mar 11 Filed by: MAYLEBEN TIMOTHY M -10.3%
4/1 Esperion Therapeutics Inc (NASDAQ: ESPR) is now covered by analysts at Bank of America Corp. They set a "buy" rating and a price target on the stock. -9.3%
11/6 Q3/2019 9/30/2019 EPS -2.520 ZacksConsensus -2.010 ActVsEst (0.510) - Miss -8.6%
3/31 Esperion Therapeutics Inc (NASDAQ: ESPR) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.9%
4/30 Esperion to Report First Quarter 2020 Financial Results May 6, 2020 -7.9%
1/24 Esperion Therapeutics Inc (NASDAQ: ESPR) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.3%
2/25 Esperion Therapeutics: The Path After FDA Approval [Seeking Alpha] -4.8%
8/30 Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -4.7%
2/14 Esperion Therapeutics Inc (NASDAQ: ESPR) was downgraded by analysts at Citigroup Inc from a "buy" rating to a "neutral" rating. -4.5%
3/12 Form 4 Esperion Therapeutics, For: Mar 11 Filed by: MAYLEBEN TIMOTHY M -10.3%
4/1 Esperion Therapeutics Inc (NASDAQ: ESPR) is now covered by analysts at Bank of America Corp. They set a "buy" rating and a price target on the stock. -9.3%
11/6 Q3/2019 9/30/2019 EPS -2.520 ZacksConsensus -2.010 ActVsEst (0.510) - Miss -8.6%
3/31 Esperion Therapeutics Inc (NASDAQ: ESPR) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.9%
4/30 Esperion to Report First Quarter 2020 Financial Results May 6, 2020 -7.9%
1/24 Esperion Therapeutics Inc (NASDAQ: ESPR) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.3%
2/25 Esperion Therapeutics: The Path After FDA Approval [Seeking Alpha] -4.8%
8/30 Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -4.7%
2/14 Esperion Therapeutics Inc (NASDAQ: ESPR) was downgraded by analysts at Citigroup Inc from a "buy" rating to a "neutral" rating. -4.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: